William Blair analyst Andy Hsieh has reiterated their bullish stance on EXEL stock, giving a Buy rating on November 3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors including the robust growth prospects of Exelixis’s Cabometyx franchise and the promising potential of Zanza. Cabometyx is expected to generate substantial cash flow through 2030, supported by its strong performance in the neuroendocrine tumors market, where it has captured a significant share of new patient prescriptions. Additionally, the company’s strategic focus on pivotal studies, such as those for post-adjuvant colorectal cancer and high-grade meningioma, positions it well for future growth.
Furthermore, Exelixis’s financial performance in the third quarter, with product sales reaching $543 million, underscores its solid market position. Although Cabometyx’s revenue was slightly below expectations, the company’s ability to manage gross-to-net adjustments effectively and maintain stable financial metrics reflects its operational strength. These factors collectively contribute to Andy Hsieh’s confidence in Exelixis’s long-term potential, justifying the Buy rating.
Hsieh covers the Healthcare sector, focusing on stocks such as Exelixis, Skye Bioscience, and Viking Therapeutics. According to TipRanks, Hsieh has an average return of 8.2% and a 45.81% success rate on recommended stocks.